Psychometric properties and clinical utility of brief measures of depression, anxiety, and general distress: The PHQ-2, GAD-2, and K-6
Psychometric properties and clinical utility of brief measures of depression, anxiety, and general distress: The PHQ-2, GAD-2, and K-6
复制标题
DOI：
10.1016/j.genhosppsych.2018.11.003
复制
发表时间：
2019-01-01
影响因子：
7
通讯作者：
Titov, Nickolai
中科院分区：
文献类型：
--
作者：
Staples, Lauren G.;Dear, Blake F.;Titov, Nickolai
目的：9项患者健康问卷（PHQ-9）、7项广泛性焦虑障碍量表（GAD-7）和10项Kessler心理困扰量表（K-10）是测量抑郁、焦虑和一般困扰的有效和可靠的工具。然而，其给药所需的时间可能会限制其在常规护理中的使用。本研究探讨了实用程序的较短的版本（PHQ-2，GAD-2，和K-6）作为筛选工具和措施的treatment respons.Method：从研究试验参与者（n=993）接受互联网提供的认知行为疗法（iCBT）的数据进行了分析，以建立判别效度的短版本。迷你国际神经精神访谈（MINI）诊断用作对照。标准组效度，重测信度，内部一致性，治疗变化的反应进行了检查。使用接受iCBT的患者在常规护理（n=1389）的数据进行重复分析。结果：PHQ-2的判别效度极佳，GAD-2和K-6的判别效度可接受。对于PHQ-2和GAD-2，可接受的灵敏度和特异性被鉴定为阈值>= 3，对于K-6，阈值>= 14。结论：PHQ-2、GAD-2和K-6是临床常规治疗中有效的筛查工具和治疗进展及转归的有效指标。
Objective: The nine-item Patient Health Questionnaire (PHQ-9), seven-item Generalized Anxiety Disorder scale (GAD-7), and ten-item Kessler Psychological Distress Scale (K-10) are valid and reliable measures of depression, anxiety and general distress. However, the time required in their administration may limit their use in routine care. This study examines the utility of shorter versions (PHQ-2, GAD-2, and K-6) as screening instruments and measures of treatment response.Method: Data from research trial participants (n=993) receiving internet-delivered cognitive behaviour therapy (iCBT) were analysed to establish discriminant validity of the short versions. Mini International Neuropsychiatric Interview (MINI) diagnoses were used as comparators. Criterion group validity, test-retest reliability, internal consistency, and responsiveness to treatment changes were examined. Analyses were replicated using data from patients receiving iCBT in routine care (n=1389).Results: Discriminant validity was excellent for the PHQ-2, and acceptable for the GAD-2 and K-6. Acceptable sensitivity and specificity were identified at a threshold of >= 3 for the PHQ-2 and GAD-2, and >= 14 for the K-6. The short versions were sensitive to treatment change.Conclusion: The PHQ-2, GAD-2 and K-6 are useful screeners and efficient measures of treatment progress and outcomes in routine clinical care.